8-K
0001162194 false00011621942024-02-282024-02-28

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): February 28, 2024

 

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of

incorporation or organization)

001-34180

(Commission File Number)

77-0513190

(I.R.S. Employer Identification Number)

2 Tower Place, Suite 2000

South San Francisco, California 94080

(Address of principal executive offices and zip code)

(650) 266-6000

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common stock, $0.001 par value per share

 

LAB

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

Item 2.02 - Results of Operations and Financial Condition

On February 28, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months and fiscal year ended December 31, 2023. The press release is attached hereto as Exhibit 99.1.

 

The information set forth in the press release, except for the information set forth under the heading “Outlook for 2024” and under the heading “About Standard BioTools Inc.,” together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

 

Item 7.01. Regulation FD Disclosure.

 

The information set forth under the heading “Outlook for 2024” and under the heading “About Standard BioTools Inc.,” together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press release issued by Standard BioTools Inc., dated February 28, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date:

 

February 28, 2024

 

 

 

 

 

 

 

 

 

STANDARD BIOTOOLS INC.

 

 

 

 

 

By:

 

/s/ Jeffrey Black

 

Name:

 

Jeffrey Black

 

Title:

 

Chief Financial Officer

 

 

 

 

 

 

 

 

 

 


EX-99.1

 

Exhibit 99.1

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins

 

Completed merger with SomaLogic, activating strategy to build scaled leader in life sciences tools and services

 

Combined pro forma revenue for FY2023 totaled $192 million and fortified balance sheet with $565 million in combined pro forma cash, cash equivalents, restricted cash and short-term investments at December 31, 20231

 

SOUTH SAN FRANCISCO, Calif., February 28, 2024 — Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.

 

Standard BioTools Stand-Alone 2023 Fourth Quarter and Full Year Selected Financial Results2

 

 

Quarter Ended

 

 

Year Ended

 

(Unaudited, in millions, except percentages)

December 31, 2023

 

 

December 31, 2023

 

Revenue

$

28.2

 

 

$

106.3

 

GAAP gross margin

 

47.4

%

 

 

47.4

%

Non-GAAP gross margin

 

59.6

%

 

 

60.1

%

Operating expenses

$

34.7

 

 

$

127.1

 

Non-GAAP operating expenses

$

24.3

 

 

$

98.6

 

Operating loss

$

(21.4

)

 

$

(76.6

)

Net loss

$

(19.8

)

 

$

(74.7

)

Non-GAAP adjusted EBITDA

$

(7.5

)

 

$

(34.7

)

Cash, cash equivalents, restricted cash,
   and short-term investments

 

 

 

$

115.7

 

Combined pro forma cash, cash equivalents,
   restricted cash and short-term investments
3

 

 

 

$

565.3

 

 

 

"In our first full year of operational execution, the Standard BioTools team hit our major target of standardizing the core business units and instilling SBS business systems throughout the organization. We also did so in one of the more challenging economic environments I’ve seen in life sciences over the last 20 years,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We have now assembled a team of seasoned operators, executing with a laser-focus on operational discipline, behind a clear strategy to bring together unique technologies under one roof. We believe this team is well positioned to achieve scale and profitability. The team has confirmed its capabilities through the ongoing reduction of expenses and cash consumption, while at the same time returning a declining business back to growth.”

 

 

 

 

 

 

 

 

1 Reflects (i) pro forma combined revenue of the Company and SomaLogic, including SomaLogic’s unaudited 2023 revenue of $86.1 million and (ii) pro forma combined cash, cash equivalents, restricted cash and short-term investments as of December 31, 2023, including SomaLogic’s unaudited cash, cash equivalents and short-term investments of $449.8 million as of December 31, 2023, in each case after giving effect to the merger with SomaLogic, which closed on January 5, 2024.

2 Unless otherwise noted financial results include only the Standard BioTools legacy business in 2023, and exclude the results of SomaLogic, which became part of Standard BioTools on January 5, 2024 and will be included in the Company’s consolidated financial statements beginning with the quarter ended March 31, 2024.

3 Reflects pro forma combined cash, cash equivalents, restricted cash and short-term investments as of December 31, 2023, including SomaLogic’s unaudited cash, cash equivalents and short-term investments of $449.8 million as of December 31, 2023, after giving effect to the merger with SomaLogic, which closed on January 5, 2024.


 

Standard BioTools Financial Highlights Compared to 2022

Total revenue increased 9% in fiscal year 2023 and 4% in the fourth quarter;
Instrument sales grew 46% in fiscal year 2023 and 44% in the fourth quarter;
Non-GAAP gross margin expanded 900 basis points to 60.1% in fiscal year 2023 and 630 basis points to 59.6% in the fourth quarter;
Non-GAAP operating expenses declined $20 million, or 17%, in fiscal year 2023 and $1 million, or 5% in the fourth quarter;
Non-GAAP adjusted EBITDA loss improved $34 million in fiscal year 2023 and over $3 million in the fourth quarter; and
Operating cash use declined $47 million, or 53%, in fiscal 2023 and $6 million, or 32%, in the fourth quarter.

 

On a combined pro forma basis, after giving effect to the merger with SomaLogic, Inc. (“SomaLogic”), total revenue for the year ended December 31, 2023 was approximately $192 million, and cash, cash equivalents, restricted cash and short-term investments at December 31, 2023 were approximately $565 million.

Egholm added, “With the recent closing of the merger with SomaLogic, we have moved into the next phase of the growth strategy. I am delighted to report that the merger integration process is well underway. We are building significant momentum and are excited to capitalize on technological and commercial potential while accelerating the collective path to profitability. We are also continuing to identify new partners with emerging technologies and businesses where together we can scale their operations, diversify our collective revenue, and empower our customers to do amazing research. We believe the best is yet to come for Standard BioTools and SomaLogic – we are better together.”

A reconciliation of non-GAAP gross margin, non-GAAP operating expenses, and non-GAAP adjusted EBITDA is provided in the financial schedules that are part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Use of Non-GAAP Financial Information.”

Outlook for 2024

For fiscal year 2024, the combined Company expects revenue in the range of $200 million to $205 million.

Conference Call Information

Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m. ET, to discuss fourth quarter and full year 2023 financial results and operational progress as well as to provide additional color on its strategic actions.

 

The Company today is providing an Investor Relations presentation with additional information on its business and operations, including an appendix with Supplemental Financial Information which is available, concurrent with this news release, on the Investor Relations page of the Company's website at Events & Presentations.

 

Live audio of the webcast will be available online along with an archived version of the webcast under the Events & Presentations page of the Company’s website.

To participate in the conference call by phone, may do so using one of the following dial-in numbers below:

US domestic callers: 1-888-346-3970
Outside US callers: 1-412-902-4297

 


 

Use of Non-GAAP Financial Information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance; expectations, operational and strategic plans; deployment of capital; market and growth opportunity and potential; the potential to realize the expected benefits following the merger of the Company and SomaLogic; and the Company’s revenue outlook for the full year 2024. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, the outcome of any legal proceedings related to the merger; risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from our restructuring, including the anticipated decrease in operational expenses, at the levels it expects; possible restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; restructuring activities, including the Company’s subleasing plans, customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the SEC today, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary

 


 

mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTubeTM. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Available Information

Standard BioTools uses its website (standardbio.com), investor site (investors.standardbio.com), corporate Twitter account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools’ website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.

 

Investor Contacts

David Holmes

Gilmartin Group LLC

(332) 330-1031

ir@standardbio.com

 


 

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

 

 

Three Months Ended December 31,

 

 

Twelve Months Ended December 31,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

(Unaudited)

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

21,384

 

 

$

20,919

 

 

$

79,198

 

 

$

72,454

 

Service and other revenue

 

 

6,804

 

 

 

6,102

 

 

 

27,142

 

 

 

25,494

 

Total revenue

 

 

28,188

 

 

 

27,021

 

 

 

106,340

 

 

 

97,948

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

 

11,666

 

 

 

13,387

 

 

 

44,942

 

 

 

52,555

 

Cost of service and other revenue

 

 

3,165

 

 

 

2,467

 

 

 

10,948

 

 

 

8,342

 

Total cost of revenue

 

 

14,831

 

 

 

15,854

 

 

 

55,890

 

 

 

60,897

 

Gross profit

 

 

13,357

 

 

 

11,167

 

 

 

50,450

 

 

 

37,051

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

6,909

 

 

 

7,425

 

 

 

25,948

 

 

 

37,382

 

Selling, general and administrative

 

 

21,354

 

 

 

20,224

 

 

 

87,541

 

 

 

102,285

 

Restructuring and related charges

 

 

1,661

 

 

 

4,630

 

 

 

7,076

 

 

 

9,732

 

Transaction-related expenses

 

 

4,819

 

 

 

 

 

 

6,485

 

 

 

3,857

 

Total operating expenses

 

 

34,743

 

 

 

32,279

 

 

 

127,050

 

 

 

153,256

 

Loss from operations

 

 

(21,386

)

 

 

(21,112

)

 

 

(76,600

)

 

 

(116,205

)

Interest expense

 

 

(1,098

)

 

 

(1,190

)

 

 

(4,567

)

 

 

(4,331

)

Loss on forward sale of Series B Preferred Stock

 

 

 

 

 

 

 

 

 

 

 

(60,081

)

Loss on Bridge Loans

 

 

 

 

 

 

 

 

 

 

 

(13,719

)

Other income (expense), net

 

 

2,546

 

 

 

1,527

 

 

 

6,963

 

 

 

1,408

 

Loss before income taxes

 

 

(19,938

)

 

 

(20,775

)

 

 

(74,204

)

 

 

(192,928

)

Income tax benefit (expense)

 

 

162

 

 

 

(70

)

 

 

(452

)

 

 

2,830

 

Net loss

 

$

(19,776

)

 

$

(20,845

)

 

$

(74,656

)

 

$

(190,098

)

Net loss per share, basic and diluted

 

$

(0.25

)

 

$

(0.26

)

 

$

(0.94

)

 

$

(2.43

)

Shares used in computing net loss per share, basic and
   diluted

 

 

79,729

 

 

 

79,434

 

 

 

79,160

 

 

 

78,305

 

 

 


 

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

 

 

December 31,
2023

 

 

December 31, 2022

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

51,704

 

 

$

81,309

 

Short-term investments

 

 

63,191

 

 

 

84,475

 

Accounts receivable, net

 

 

19,660

 

 

 

17,280

 

Inventories, net

 

 

20,533

 

 

 

21,473

 

Prepaid expenses and other current assets

 

 

3,127

 

 

 

4,278

 

Total current assets

 

 

158,215

 

 

 

208,815

 

Property and equipment, net

 

 

24,187

 

 

 

25,652

 

Operating lease right-of-use asset, net

 

 

30,663

 

 

 

33,883

 

Other non-current assets

 

 

2,285

 

 

 

3,109

 

Developed technology, net

 

 

1,400

 

 

 

12,600

 

Goodwill

 

 

106,317

 

 

 

106,251

 

Total assets

 

$

323,067

 

 

$

390,310

 

 

 

 

 

 

 

 

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

9,236

 

 

$

7,914

 

Accrued compensation and related benefits

 

 

11,867

 

 

 

9,153

 

Operating lease liabilities, current

 

 

4,323

 

 

 

3,682

 

Deferred revenue, current

 

 

11,607

 

 

 

10,792

 

Deferred grant income, current

 

 

3,612

 

 

 

3,644

 

Other accrued liabilities

 

 

9,152

 

 

 

6,175

 

Term loan, current

 

 

5,000

 

 

 

2,083

 

Convertible notes, current

 

 

54,530

 

 

 

 

Total current liabilities

 

 

109,327

 

 

 

43,443

 

Convertible notes, non-current

 

 

569

 

 

 

54,615

 

Term loan, non-current

 

 

3,414

 

 

 

8,194

 

Deferred tax liability

 

 

841

 

 

 

1,055

 

Operating lease liabilities, non-current

 

 

30,374

 

 

 

34,081

 

Deferred revenue, non-current

 

 

3,520

 

 

 

3,816

 

Deferred grant income, non-current

 

 

10,755

 

 

 

14,359

 

Other non-current liabilities

 

 

1,065

 

 

 

961

 

Total liabilities

 

 

159,865

 

 

 

160,524

 

Mezzanine equity:

 

 

 

 

 

 

Redeemable preferred stock

 

 

311,253

 

 

 

311,253

 

Total stockholders’ deficit

 

 

(148,051

)

 

 

(81,467

)

Total liabilities, mezzanine equity and stockholders’ deficit

 

$

323,067

 

 

$

390,310

 

 

 


 

STANDARD BIOTOOLS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

 

Twelve Months Ended December 31,

 

 

2023

 

 

2022

 

Operating activities

 

 

 

 

 

 

Net loss

 

$

(74,656

)

 

$

(190,098

)

Loss on forward sale of Series B Preferred Stock

 

 

 

 

 

60,081

 

Loss on bridge loans

 

 

 

 

 

13,719

 

Stock-based compensation expense

 

 

13,123

 

 

 

14,880

 

Amortization of developed technology

 

 

11,200

 

 

 

11,528

 

Depreciation and amortization

 

 

3,980

 

 

 

3,499

 

Provision for excess and obsolete inventory

 

 

1,496

 

 

 

7,874

 

Impairment of InstruNor developed technology intangible

 

 

 

 

 

3,526

 

Amortization of debt discounts, premiums and issuance costs

 

 

770

 

 

 

830

 

Other non-cash items

 

 

(987

)

 

 

273

 

Changes in assets and liabilities, net

 

 

1,787

 

 

 

(15,482

)

Net cash used in operating activities

 

 

(43,287

)

 

 

(89,370

)

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

Purchases of short-term investments

 

 

(94,896

)

 

 

(137,302

)

Proceeds from sales and maturities of investments

 

 

117,964

 

 

 

53,000

 

Purchases of property and equipment

 

 

(2,831

)

 

 

(3,825

)

Net cash provided by (used in) investing activities

 

 

20,237

 

 

 

(88,127

)

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

 

Proceeds from bridge loans

 

 

 

 

 

25,000

 

Proceeds from issuance of Series B Preferred Stock

 

 

 

 

 

225,000

 

Repayment of term loan and advances under revolving credit facility

 

 

(2,083

)

 

 

(6,838

)

Payment of debt and equity issuance costs

 

 

 

 

 

(12,547

)

Repurchase of common stock

 

 

(5,414

)

 

 

(563

)

Proceeds from ESPP stock issuance

 

 

827

 

 

 

917

 

Payments for taxes related to net share settlement of equity awards and other

 

 

(139

)

 

 

(211

)

Net cash provided by (used in) financing activities

 

 

(6,809

)

 

 

230,758

 

Effect of foreign exchange rate fluctuations on cash and cash equivalents

 

 

34

 

 

 

(404

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

(29,825

)

 

 

52,857

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

82,324

 

 

 

29,467

 

Cash, cash equivalents and restricted cash at end of period

 

$

52,499

 

 

$

82,324

 

 

 

 

 

 

 

 

Cash, cash equivalents, and restricted cash consists of:

 

 

 

 

 

 

Cash and cash equivalents

 

$

51,704

 

 

$

81,309

 

Restricted cash

 

 

795

 

 

 

1,015

 

Total cash, cash equivalents and restricted cash

 

$

52,499

 

 

$

82,324

 

 

 


 

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE

 

 

Three Months Ended December 31,

 

 

Twelve Months Ended December 31,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

GAAP gross profit

 

$

13,357

 

 

$

11,167

 

 

$

50,450

 

 

$

37,051

 

Amortization of developed technology

 

 

2,800

 

 

 

2,800

 

 

 

11,200

 

 

 

11,208

 

Depreciation and amortization

 

 

482

 

 

 

297

 

 

 

1,473

 

 

 

1,245

 

Stock-based compensation expense

 

 

163

 

 

 

133

 

 

 

811

 

 

 

592

 

Non-GAAP gross profit

 

$

16,802

 

 

$

14,397

 

 

$

63,934

 

 

$

50,096

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP gross margin percentage

 

 

47.4

%

 

 

41.3

%

 

 

47.4

%

 

 

37.8

%

Amortization of developed technology

 

 

9.9

%

 

 

10.4

%

 

 

10.5

%

 

 

11.4

%

Depreciation and amortization

 

 

1.7

%

 

 

1.1

%

 

 

1.4

%

 

 

1.3

%

Stock-based compensation expense

 

 

0.6

%

 

 

0.5

%

 

 

0.8

%

 

 

0.6

%

Non-GAAP gross margin percentage

 

 

59.6

%

 

 

53.3

%

 

 

60.1

%

 

 

51.1

%

 

 


 

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES

 

 

Three Months Ended December 31,

 

 

Twelve Months Ended December 31,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

GAAP operating expenses

 

$

34,743

 

 

$

32,279

 

 

$

127,050

 

 

$

153,256

 

Restructuring and related charges

 

 

(1,661

)

 

 

(4,630

)

 

 

(7,076

)

 

 

(9,732

)

Transaction-related expenses

 

 

(4,819

)

 

 

 

 

 

(6,485

)

 

 

(3,857

)

Stock-based compensation expense

 

 

(3,312

)

 

 

(1,548

)

 

 

(12,312

)

 

 

(14,288

)

Depreciation and amortization

 

 

(624

)

 

 

(523

)

 

 

(2,507

)

 

 

(2,575

)

Impairment of intangible assets

 

 

 

 

 

 

 

 

 

 

 

(3,526

)

Loss on disposal of property and equipment

 

 

 

 

 

(100

)

 

 

(73

)

 

 

(312

)

Non-GAAP operating expenses

 

$

24,327

 

 

$

25,478

 

 

$

98,597

 

 

$

118,966

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP R&D operating expenses

 

$

6,909

 

 

$

7,425

 

 

$

25,948

 

 

$

37,382

 

Stock-based compensation expense

 

 

(430

)

 

 

(467

)

 

 

(1,671

)

 

 

(2,481

)

Depreciation and amortization

 

 

(125

)

 

 

(150

)

 

 

(526

)

 

 

(954

)

Impairment of intangible assets

 

 

 

 

 

 

 

 

 

 

 

(3,526

)

Non-GAAP R&D operating expenses

 

$

6,354

 

 

$

6,808

 

 

$

23,751

 

 

$

30,421

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP SG&A operating expenses

 

$

21,354

 

 

$

20,224

 

 

$

87,541

 

 

$

102,285

 

Stock-based compensation expense

 

 

(2,882

)

 

 

(1,081

)

 

 

(10,641

)

 

 

(11,807

)

Depreciation and amortization

 

 

(499

)

 

 

(373

)

 

 

(1,981

)

 

 

(1,621

)

Loss on disposal of property and equipment

 

 

 

 

 

(100

)

 

 

(73

)

 

 

(312

)

Non-GAAP SG&A operating expenses

 

$

17,973

 

 

$

18,670

 

 

$

74,846

 

 

$

88,545

 

 

 


 

STANDARD BIOTOOLS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(In thousands)

(Unaudited)

ITEMIZED RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA

 

 

Three Months Ended December 31,

 

 

Twelve Months Ended December 31,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

GAAP net loss

 

$

(19,776

)

 

$

(20,845

)

 

$

(74,656

)

 

$

(190,098

)

Income tax expense (benefit)

 

 

(162

)

 

 

70

 

 

 

452

 

 

 

(2,830

)

Interest expense

 

 

1,098

 

 

 

1,190

 

 

 

4,567

 

 

 

4,331

 

Amortization of developed technology

 

 

2,800

 

 

 

2,800

 

 

 

11,200

 

 

 

11,528

 

Depreciation and amortization

 

 

1,106

 

 

 

819

 

 

 

3,980

 

 

 

3,499

 

Restructuring and related charges

 

 

1,661

 

 

 

4,630

 

 

 

7,076

 

 

 

9,732

 

Transaction-related expenses

 

 

4,819

 

 

 

 

 

 

6,485

 

 

 

3,857

 

Stock-based compensation expense

 

 

3,475

 

 

 

1,681

 

 

 

13,123

 

 

 

14,880

 

Impairment of intangible assets

 

 

 

 

 

 

 

 

 

 

 

3,526

 

Loss on forward sale of Series B Preferred Stock

 

 

 

 

 

 

 

 

 

 

 

60,081

 

Loss on bridge loans

 

 

 

 

 

 

 

 

 

 

 

13,719

 

Other non-operating expense (income)

 

 

(2,546

)

 

 

(1,527

)

 

 

(6,963

)

 

 

(1,408

)

Loss on disposal of property and equipment

 

 

 

 

 

100

 

 

 

73

 

 

 

312

 

Non-GAAP adjusted EBITDA

 

$

(7,525

)

 

$

(11,082

)

 

$

(34,663

)

 

$

(68,871

)

 

CALCULATION OF OPERATING CASH USE

 

 

Three Months Ended December 31,

 

 

Twelve Months Ended December 31,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net cash used in operating activities (1)

 

$

(14,061

)

 

$

(19,181

)

 

$

(43,287

)

 

$

(89,370

)

Purchases of property and equipment

 

 

(78

)

 

 

(755

)

 

 

(2,831

)

 

 

(3,825

)

Cash paid for interest

 

 

1,648

 

 

 

1,646

 

 

 

3,819

 

 

 

3,493

 

Operating cash use

 

$

(12,491

)

 

$

(18,290

)

 

$

(42,299

)

 

$

(89,702

)

 

(1) Derived from the Condensed Consolidated Statements of Cash Flows.